$2.47
4.66% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US98986M1036
Symbol
ZYXI

Zynex, Inc. Stock price

$2.47
+0.34 15.96% 1M
-5.39 68.58% 6M
-5.54 69.16% YTD
-8.09 76.61% 1Y
-4.78 65.93% 3Y
-14.47 85.42% 5Y
+2.27 1,125.81% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.11 4.66%
ISIN
US98986M1036
Symbol
ZYXI
Sector

Key metrics

Market capitalization $74.69m
Enterprise Value $123.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.72
P/S ratio (TTM) P/S ratio 0.43
P/B ratio (TTM) P/B ratio 3.59
Revenue growth (TTM) Revenue growth -8.63%
Revenue (TTM) Revenue $172.40m
EBIT (operating result TTM) EBIT $-7.63m
Free Cash Flow (TTM) Free Cash Flow $-440.00k
Cash position $23.85m
EPS (TTM) EPS $-0.24
P/E forward negative
P/S forward 0.64
EV/Sales forward 1.06
Short interest 24.14%
Show more

Is Zynex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Zynex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Zynex, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Zynex, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Zynex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
172 172
9% 9%
100%
- Direct Costs 39 39
0% 0%
22%
134 134
11% 11%
78%
- Selling and Administrative Expenses 137 137
2% 2%
79%
- Research and Development Expense - -
-
-
-2.85 -2.85
118% 118%
-2%
- Depreciation and Amortization 4.78 4.78
0% 0%
3%
EBIT (Operating Income) EBIT -7.63 -7.63
169% 169%
-4%
Net Profit -7.41 -7.41
191% 191%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Zynex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zynex, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
PRNewsWire
one day ago
NEW YORK , May 19, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the "Class Period"), of the important May 19, 2025 lead plaintiff deadline. So What: If you purchased Zynex securities during the Class Period you may be entitled to compen...
Neutral
GlobeNewsWire
3 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options
More Zynex, Inc. News

Company Profile

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Head office United States
CEO Thomas Sandgaard
Employees 1,000
Founded 1996
Website www.zynex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today